EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Potassium-competitive acid blockers and proton-pump inhibitors for the healing and maintenance of erosive esophagitis: a comprehensive and updated systematic review with network meta-analysis

Daniel Martin Simadibrata, Thai Hau Koo, Raúl Alberto Jiménez-Castillo, Ronnie Fass

Esophagus · 2026-10 · 23 (4) · 702-713

DOI: 10.1007/s10388-026-01222-2 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Esophagus, online erschienen am 15.06.2026. Verfasst von Daniel Martin Simadibrata und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Esophagitis, Esophagitis, Peptic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Randomized controlled trials (RCTs) suggest that potassium-competitive acid blockers (PCABs) are non-inferior to standard-dose proton pump inhibitors (PPIs) for erosive esophagitis (EE). However, direct comparative data against double-dose or dual-delayed release PPIs remain limited. This network meta-analysis (NMA) ranks the efficacy of PCABs and PPIs (standard, double, and dual-delayed-release doses) for EE healing and maintenance. A systematic search of MEDLINE, EMBASE, and the Cochrane Library from inception through February 2, 2025 (updated on December 15, 2025) identified RCTs comparing PCABs or PPIs in adults with endoscopically confirmed EE or previously healed EE. Primary outcomes were EE healing at weeks 4 and 8, and maintenance at 6 months. A frequentist NMA estimated risk ratios (RRs) with 95% confidence intervals (95%CI), using vonoprazan 20 mg once daily (QD) and 10 mg QD as reference for healing and maintenance studies, respectively; ranking metrics (P-scores) were used descriptively. A total of 99 RCTs were included. At week 4, several regimens showed similar healing rate to vonoprazan 20 mg QD, including linaprazan 75 mg BID, linaprazan 50 mg BID, and zastaprazan 20 mg QD. At week 8, zastaprazan 20 mg QD was significantly better than vonoprazan 20 mg QD (RR 1.10; 95%CI 1.01–1.21; P-score = 0.92). For maintenance at 6 months, several standard-dose regimens (including esomeprazole 40 mg QD and vonoprazan 20 mg QD) showed similar efficacy, whereas lower-dose PPIs performed worse. Adverse events were comparable across therapies. Zastaprazan 20 mg QD and esomeprazole 40 mg QD demonstrated the highest efficacy for EE healing and maintenance, respectively. Overall, PCABs did not consistently outperform dual-delayed release or double-dose PPIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsEsophagitisEsophagitis, PepticHumansRandomized Controlled Trials as TopicPyrrolesSulfonamides

Stichwörter der Autor:innen

Erosive esophagitisHistamine-2 receptor antagonistNetwork meta-analysisPotassium-competitive acid blockerProton pump inhibitor

Substanzen

Proton Pump InhibitorsvonoprazanPyrrolesSulfonamides

Autor:innen und Institutionen

  • Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA.
  • Division of Gastroenterology and Hepatology, The Esophageal and Swallowing Center, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA.
  • Division of Gastroenterology and Hepatology, The Esophageal and Swallowing Center, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA. rfass@metrohealth.org.

Zitieren

APA

Simadibrata, D. M., Koo, T. H., Jiménez-Castillo, R. A., & Fass, R. (2026). Potassium-competitive acid blockers and proton-pump inhibitors for the healing and maintenance of erosive esophagitis: a comprehensive and updated systematic review with network meta-analysis. Esophagus, 23(4), 702-713. https://doi.org/10.1007/s10388-026-01222-2

Vancouver

Simadibrata DM, Koo TH, Jiménez-Castillo RA, Fass R. Potassium-competitive acid blockers and proton-pump inhibitors for the healing and maintenance of erosive esophagitis: a comprehensive and updated systematic review with network meta-analysis. Esophagus. 2026;23(4):702-713. doi:10.1007/s10388-026-01222-2

BibTeX
@article{Simadibrata2026,
  author = {Simadibrata, Daniel Martin and Koo, Thai Hau and Jiménez-Castillo, Raúl Alberto and Fass, Ronnie},
  title = {Potassium-competitive acid blockers and proton-pump inhibitors for the healing and maintenance of erosive esophagitis: a comprehensive and updated systematic review with network meta-analysis},
  journal = {Esophagus},
  year = {2026},
  volume = {23},
  number = {4},
  pages = {702--713},
  doi = {10.1007/s10388-026-01222-2}
}
Kostenlos starten →